FDA has amended the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the spike protein from the SARS-CoV-2 omicron variant lineage XBB.1.5.
That's a lot of letters but, just like the flu, if you have one of the big five co-morbidities, get it.
If you never had the prior vaccine, this will be two shots, three weeks apart.
FDA Approves Novavax COVID-19 Vaccine With SARS-CoV-2 Omicron Variant Lineage XBB.1.5
Related articles
- Hong Kong Had 90% Fewer COVID-19 Deaths After Booster Shots
- How The COVID-19 Omicron Subvariant BA.5 Became A Deadly Master Of Disguise
- Ad26.COV2.S: Single-Shot COVID-19 Vaccine Successful In Rhesus Macaques
- COVID-19 Vaccination Reduced Odds Of SARS-CoV-2 Infection, As Did Staying In A Separate Room From Infected People
- Why We Can't Just Let Omicron Spread- Urban Legend That Viruses Evolve Naturally To Be Mild- Need To Control With #DOITALL
Comments